Exact Sciences stock swells on revised guidelines for colorectal cancer screening

Exact Sciences stock jumped as much as 13 percent on Wednesday after the American Cancer Society said people should be screened for colorectal cancer at age 45, lowering its guidelines from the current recommended age of 50.

Exact, of Madison, makes Cologuard, a stool test for colorectal cancer. More than 1.1 million people have used the home test kit since it was approved by federal regulators in 2014.